www.exscientia.com Open in urlscan Pro
83.223.102.104  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * ABOUT
   
   ABOUT
   
    * OUR MISSION
    * OUR VALUES
    * TEAM

 * PATIENT-FIRST AI
   
   PATIENT-FIRST AI
   
    * PRECISION TARGET
    * PRECISION DESIGN
    * PRECISION EXPERIMENT
    * PRECISION MEDICINE
    * PRESENTATIONS
    * PUBLICATIONS

 * PIPELINE
 * INVESTORS & MEDIA
   
   INVESTORS & MEDIA
   
    * OVERVIEW
    * PRESS RELEASES
    * EVENTS & PRESENTATIONS
    * STOCK INFORMATION
    * CORPORATE GOVERNANCE
    * FINANCIALS & FILINGS
    * INVESTOR RESOURCES

 * JOIN US
 * CONTACT

 * ABOUT
   
   ABOUT
   
    * ABOUT
    * OUR MISSION
    * OUR VALUES
    * TEAM

 * PATIENT-FIRST AI
   
   PATIENT-FIRST AI
   
    * PATIENT-FIRST AI
    * PRECISION TARGET
    * PRECISION DESIGN
    * PRECISION EXPERIMENT
    * PRECISION MEDICINE
    * PRESENTATIONS
    * PUBLICATIONS

 * PIPELINE
 * INVESTORS & MEDIA
   
   INVESTORS & MEDIA
   
    * INVESTORS & MEDIA
    * OVERVIEW
    * PRESS RELEASES
    * EVENTS & PRESENTATIONS
    * STOCK INFORMATION
    * CORPORATE GOVERNANCE
    * FINANCIALS & FILINGS
    * INVESTOR RESOURCES

 * JOIN US
 * CONTACT


IN THE FUTURE ALL DRUGS WILL BE DESIGNED BY AI.





DARWIN’S TREE.

Tree of knowledge. Tree of life.

Exscientia’s tree sculpture logo is based on a sketch found in Darwin’s notebook
where he first proposed a theory of evolution and natural selection. Developing
AI to be creative follows similar principles to evolution to generate new ideas
and using models to select the best.

Explore

BETTER DRUGS, FASTER

Welcome to the world’s leading technology-driven drug design company. We work at
the interface of AI, human ingenuity and physical engineering to precision
design future drugs for patients and revolutionise drug discovery.


 * CLINICAL IMPACT
   
   GROUND-BREAKING CLINICAL IMPACT. OUR PATIENT-FIRST AI PLATFORM HAS ALREADY
   DEMONSTRATED IMPROVED TREATMENT OUTCOMES IN A PROSPECTIVE INTERVENTIONAL
   STUDY.
   
   Learn More
   


 * OUR PIPELINE
   
   WE COMBINE PRECISION DESIGN, THE DELIBERATE PLACEMENT OF EACH ATOM IN A
   COMPOUND, WITH INTEGRATED EXPERIMENT, THE ABILITY TO EMBED EXPERIMENTATION
   INTO OUR TECHNOLOGY PLATFORM TO PROGRESS A PIPELINE OF DRUG CANDIDATES.
   
   Learn More
   

 * WORLD FIRST
   
   EXSCIENTIA IS SPEARHEADING THE DRUG DISCOVERY REVOLUTION WITH THE FIRST
   AI-DESIGNED MOLECULES TO REACH CLINICAL TRIALS.
   
   


 * CLINICAL IMPACT
   
   GROUND-BREAKING CLINICAL IMPACT. OUR PATIENT-FIRST AI PLATFORM HAS ALREADY
   DEMONSTRATED IMPROVED TREATMENT OUTCOMES IN A PROSPECTIVE INTERVENTIONAL
   STUDY.
   
   Learn More
   


 * OUR PIPELINE
   
   WE COMBINE PRECISION DESIGN, THE DELIBERATE PLACEMENT OF EACH ATOM IN A
   COMPOUND, WITH INTEGRATED EXPERIMENT, THE ABILITY TO EMBED EXPERIMENTATION
   INTO OUR TECHNOLOGY PLATFORM TO PROGRESS A PIPELINE OF DRUG CANDIDATES.
   
   Learn More
   

 * WORLD FIRST
   
   EXSCIENTIA IS SPEARHEADING THE DRUG DISCOVERY REVOLUTION WITH THE FIRST
   AI-DESIGNED MOLECULES TO REACH CLINICAL TRIALS.
   
   


 * CLINICAL IMPACT
   
   GROUND-BREAKING CLINICAL IMPACT. OUR PATIENT-FIRST AI PLATFORM HAS ALREADY
   DEMONSTRATED IMPROVED TREATMENT OUTCOMES IN A PROSPECTIVE INTERVENTIONAL
   STUDY.
   
   Learn More
   

 * 
 * 
 * 

 * SMARTER DESIGN DECISIONS WITH AI
   
   NAVIGATING CHEMICAL SPACE
   
   Whilst there are trillions of potential molecules, few will ever be made and
   only a handful fulfill the complex criteria required to warrant testing in
   the clinic.
   
   LEARNING EFFICIENTLY WITH AI
   
   Drug discovery is best thought of as a learning problem. Faster learning
   identifies compounds that fit a project’s clinical brief more rapidly and
   efficiently.
   
   EXSCIENTIA AI PLATFORM
   
   Our AI systems are better at learning than traditional human-led design
   allowing molecules to reach the clinic faster.

 * HIGHER PERFORMANCE WITH AI
   
   EFFICIENT
   
   We only need to test 1/10th of the compounds traditionally required.
   
   QUALITY
   
   We design against key criteria from the outset baking in all the properties
   needed for a successful drug.
   
   UNPRECEDENTED SPEED
   
   From project start to candidate molecule in less than 1 year.

 * APPLYING AI TO DRUG DESIGN IS RECOGNISED AS ONE OF THE ULTIMATE SCIENTIFIC
   CHALLENGES
   
   

 * SMARTER DESIGN DECISIONS WITH AI
   
   NAVIGATING CHEMICAL SPACE
   
   Whilst there are trillions of potential molecules, few will ever be made and
   only a handful fulfill the complex criteria required to warrant testing in
   the clinic.
   
   LEARNING EFFICIENTLY WITH AI
   
   Drug discovery is best thought of as a learning problem. Faster learning
   identifies compounds that fit a project’s clinical brief more rapidly and
   efficiently.
   
   EXSCIENTIA AI PLATFORM
   
   Our AI systems are better at learning than traditional human-led design
   allowing molecules to reach the clinic faster.

 * HIGHER PERFORMANCE WITH AI
   
   EFFICIENT
   
   We only need to test 1/10th of the compounds traditionally required.
   
   QUALITY
   
   We design against key criteria from the outset baking in all the properties
   needed for a successful drug.
   
   UNPRECEDENTED SPEED
   
   From project start to candidate molecule in less than 1 year.

 * APPLYING AI TO DRUG DESIGN IS RECOGNISED AS ONE OF THE ULTIMATE SCIENTIFIC
   CHALLENGES
   
   

 * SMARTER DESIGN DECISIONS WITH AI
   
   NAVIGATING CHEMICAL SPACE
   
   Whilst there are trillions of potential molecules, few will ever be made and
   only a handful fulfill the complex criteria required to warrant testing in
   the clinic.
   
   LEARNING EFFICIENTLY WITH AI
   
   Drug discovery is best thought of as a learning problem. Faster learning
   identifies compounds that fit a project’s clinical brief more rapidly and
   efficiently.
   
   EXSCIENTIA AI PLATFORM
   
   Our AI systems are better at learning than traditional human-led design
   allowing molecules to reach the clinic faster.

 * 
 * 
 * 

 * REVOLUTIONISING DRUG DISCOVERY
   
   The pharmaceutical industry has only recently acknowledged the potential of
   AI. Projects still routinely require 2,500-5,000 molecules to be made over
   many years before a single compound suitable for clinical testing can be
   trialled.
   
   Exscientia challenges the need for this by leveraging active learning to
   maximise information gain for design, make, test, learn cycles.
   
   FASTER BY DESIGN
   
   At Exscientia we put AI algorithms at the heart of design and data
   interpretation.
   
   
   
   BETTER BY DESIGN
   
   Our AI systems optimise properties in parallel rather than sequentially.

 * BETTER BY DESIGN
   
   Using AI to design and optimise molecular properties in parallel, rather than
   sequentially, increases the likelihood of discovering a candidate with
   exquisitely balanced pharmacology that will deliver therapeutic benefit in
   the clinic.
   
   FASTER BY DESIGN
   
   By putting AI at the heart of design as well as data interpretation, we put
   faith in its ability to rapidly identify optimal drug discovery paths.
   Through more efficient learning the systems determine the next step faster
   than incumbent methods.
   
   PRECISION DESIGN
   
   The results speak for themselves, with high quality clinical molecules being
   invented within a fraction of the compounds typically required, dramatically
   shortening the path to the clinic.

 * REVOLUTIONISING DRUG DISCOVERY
   
   The pharmaceutical industry has only recently acknowledged the potential of
   AI. Projects still routinely require 2,500-5,000 molecules to be made over
   many years before a single compound suitable for clinical testing can be
   trialled.
   
   Exscientia challenges the need for this by leveraging active learning to
   maximise information gain for design, make, test, learn cycles.
   
   FASTER BY DESIGN
   
   At Exscientia we put AI algorithms at the heart of design and data
   interpretation.
   
   
   
   BETTER BY DESIGN
   
   Our AI systems optimise properties in parallel rather than sequentially.

 * BETTER BY DESIGN
   
   Using AI to design and optimise molecular properties in parallel, rather than
   sequentially, increases the likelihood of discovering a candidate with
   exquisitely balanced pharmacology that will deliver therapeutic benefit in
   the clinic.
   
   FASTER BY DESIGN
   
   By putting AI at the heart of design as well as data interpretation, we put
   faith in its ability to rapidly identify optimal drug discovery paths.
   Through more efficient learning the systems determine the next step faster
   than incumbent methods.
   
   PRECISION DESIGN
   
   The results speak for themselves, with high quality clinical molecules being
   invented within a fraction of the compounds typically required, dramatically
   shortening the path to the clinic.

 * REVOLUTIONISING DRUG DISCOVERY
   
   The pharmaceutical industry has only recently acknowledged the potential of
   AI. Projects still routinely require 2,500-5,000 molecules to be made over
   many years before a single compound suitable for clinical testing can be
   trialled.
   
   Exscientia challenges the need for this by leveraging active learning to
   maximise information gain for design, make, test, learn cycles.
   
   FASTER BY DESIGN
   
   At Exscientia we put AI algorithms at the heart of design and data
   interpretation.
   
   
   
   BETTER BY DESIGN
   
   Our AI systems optimise properties in parallel rather than sequentially.

 * BETTER BY DESIGN
   
   Using AI to design and optimise molecular properties in parallel, rather than
   sequentially, increases the likelihood of discovering a candidate with
   exquisitely balanced pharmacology that will deliver therapeutic benefit in
   the clinic.
   
   FASTER BY DESIGN
   
   By putting AI at the heart of design as well as data interpretation, we put
   faith in its ability to rapidly identify optimal drug discovery paths.
   Through more efficient learning the systems determine the next step faster
   than incumbent methods.
   
   PRECISION DESIGN
   
   The results speak for themselves, with high quality clinical molecules being
   invented within a fraction of the compounds typically required, dramatically
   shortening the path to the clinic.

 * 
 * 

DRUG DISCOVERY IS A
LEARNING CHALLENGE

Faster learning shortens discovery times and improves outcomes. AI is simply
better at learning from complex data sets than humans and better at determining
what to do next. We demonstrated this with our ‘Human vs Machine’ data,
published in Nature.

PATIENT-FIRST AI

Empowering target selection, precision design and experiment, as well as
enhanced clinical assessment utilising high-precision information from viable
patient tissue.

Together we make unparalleled progress




Learn More

CAREERS AT EXSCIENTIA

Join us on our mission

We are a creative, passionate and collaborative organisation dedicated to
setting bold new standards in drug discovery and design. If you have the
ingenuity, energy and ambition to help us change the world, we would love to
hear from you.

Open Positions
The Schrödinger Building
Oxford Science Park,
Oxford
OX4 4GE


Phone: +44 (0) 1865 818941

COMPANY

 * Join us
 * Contact
 * Expanded Access Policy
 * Privacy Policy
 * Recruitment Privacy Policy
 * Anti Slavery Policy

ABOUT US

 * Our Mission
 * Our Values
 * Team
 * Investors & Media

PATIENT-FIRST AI

 * Patient-first AI
 * Precision Target
 * Precision Design
 * Precision Experiment
 * Precision Medicine
 * Presentations
 * Publications

SOCIAL

 * 
 *